PPARA and metabolic syndrome: Pemafibrate (K‐877), a selective PPAR modulator, improved dyslipidemia, transaminase levels, and MASH pathology in animal studies [253], while also reducing hepatic inflammation and upregulating fatty acid oxidation genes in human trials [254, 255].